Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PXS-6302 topical cream for established burn or surgical scars
ACTRN12621001545853Phase 2Not yet recruiting
- Sponsor
- The University of Western Australia
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of PXS-6302 in severe cutaneous adverse reactions (SCAR), burn scar and surgical scar (2 arms), sponsored by The University of Western Australia. Primary endpoint: Safety and tolerability of multiple applications of PXS-6302 versus placebo. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
PXS-6302
03
Conditions
severe cutaneous adverse reactions (SCAR)burn scarsurgical scar
Beyond the preview
Go deeper on ACTRN12621001545853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001545853.